Table 1 Baseline patient characteristics of the unmatched population
Diabetes (n = 3550) | No diabetes (n = 7890) | p-value | |
|---|---|---|---|
Demographics | |||
Age (years) | 80 ± 7 | 82 ± 7 | < 0.001 |
Women | 1893 (53%) | 4655 (59%) | < 0.001 |
Body mass index (kg/m2) | 28 ± 5 | 26 ± 5 | < 0.001 |
Body surface area (m2) | 1.79 ± 0.19 | 1.73 ± 0.19 | < 0.001 |
Medical history | |||
Stroke or TIA | 410 (12%) | 770 (10%) | 0.004 |
Myocardial infarction | 615 (17%) | 933 (12%) | < 0.001 |
Previous PCI | 889 (25%) | 1514 (19%) | < 0.001 |
Previous CABG | 579 (16%) | 852 (11%) | < 0.001 |
Hypertension | 3040 (86%) | 5492 (75%) | < 0.001 |
Dyslipidaemia | 2396 (68%) | 3878 (49%) | < 0.001 |
Peripheral vascular disease | 640 (18%) | 1090 (14%) | < 0.001 |
Coronary artery disease | 1707 (48%) | 3025 (38%) | < 0.001 |
Atrial fibrillation | 945 (27%) | 2148 (27%) | 0.50 |
Renal failure | 467 (13%) | 1089 (14%) | 0.35 |
GFR (ml/min/1.73m2) | 52.4 (38.3–69.9) | 52.3 (38.9–68.9) | 0.73 |
NYHA ≥ 3 | 776 (39%) | 2000 (46%) | < 0.001 |
Risk scores | |||
Logistic EuroSCORE (%) | 15.5 (9.5–23.6) | 15.0 (9.5–22.9) | 0.05 |
STS-PROM (%) | 7.0 (4.1–13.5) | 6.1 (3.9–12.8) | < 0.001 |
EuroSCORE II (%) | 4.7 (2.7–8.2) | 3.7 (2.2-6.0) | < 0.001 |
Medication | |||
Statin | 480 (73%) | 932 (65%) | < 0.001 |
Aspirin | 1090 (68%) | 2593 (64%) | 0.002 |
Clopidogrel | 473 (47%) | 1089 (41%) | < 0.001 |
Oral anticoagulation | 558 (32%) | 1291 (33%) | 0.33 |
Echocardiographic characteristics | |||
LVEF (%) | 55 ± 14 | 56 ± 14 | 0.005 |
Max gradient (mmHg) | 76 ± 22 | 81 ± 24 | < 0.001 |
Mean gradient (mmHg) | 50 ± 17 | 52 ± 17 | < 0.001 |
Aortic valve area (cm2) | 0.66 ± 0.19 | 0.67 ± 0.20 | 0.33 |
Stroke volume (mL) | 29 ± 8 | 29 ± 7 | 0.42 |
Stroke volume index (mL/m2) | 16 ± 5 | 17 ± 4 | < 0.001 |
Device Type | |||
Balloon-expandable valve | 1918 (54%) | 4191 (53%) | 0.37 |
Third generation valve | 1101 (33%) | 2038 (28%) | < 0.001 |